A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)

OBJECTIVE: To evaluate the efficacy and safety of AVP-825, a drug–device combination of low-dose sumatriptan powder (22 mg loaded dose) delivered intranasally through a targeted Breath Powered device vs an identical device containing lactose powder (placebo device) in the treatment of migraine heada...

Descripción completa

Detalles Bibliográficos
Autores principales: Cady, Roger K, McAllister, Peter J, Spierings, Egilius LH, Messina, John, Carothers, Jennifer, Djupesland, Per G, Mahmoud, Ramy A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320758/
https://www.ncbi.nlm.nih.gov/pubmed/25355310
http://dx.doi.org/10.1111/head.12472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320758/
https://www.ncbi.nlm.nih.gov/pubmed/25355310
http://dx.doi.org/10.1111/head.12472

Ejemplares similares